16, 17 Protein extracts from human liver tumors and from healthy

16, 17 Protein extracts from human liver tumors and from healthy patients were obtained from OriGene (Rockville, MD). Liver tumors were induced in wild-type (WT) and Little mice via diethylnitrosoamine (DEN) tumor liver

induction as described.5 For FXR agonist treatment experiment, 8-week-old mice were injected with FXR agonist GW4064 intraperitoneally (30 mg/kg body weight). Alvelestat mouse Control mice were injected with vehicle (corn oil). Nuclear and cytoplasmic extract isolation and western blot analysis were performed as described our previous publications.18, 19 A typical picture of the quality of the separation of cytoplasmic and nuclear proteins is shown in Supporting Fig. 2. Total RNA from liver tissues or Hep3B2 cells was extracted with an RNeasy Mini Kit (Qiagen,

Germantown, MD) according to the manufacturer’s instructions. Complementary DNA was synthesized using SuperScript III First-strand (Invitrogen) and random primer hexamers. The primer sequences used in the studies are presented in the Supporting Information. Chromatin immunoprecipitation assay (ChIP) was performed as described5, 18 using the ChIP-IT kit (Active Motif, Carlsbad, CA). Electrophoretic mobility shift assay was performed as described.19 Antibodies to FXR (C20 and H130), gankyrin, C/EBPβ (C19), C/EBPα (A144), cdk4, cdc2, cyclin D3, Rb, p53, and HDAC1 (H-51) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to acetyl-histone H3 (Lys9) and histone H3 trimethyl Lys9 were obtained from Abcam (Cambridge, MA). Monoclonal anti–β-actin antibody was from Sigma (St. Louis, MO). The bromodeoxyuridine NVP-AUY922 (BrdU) uptake

assay kit was obtained from Invitrogen (Carlsbad, CA). Co-immunoprecipitation studies were performed using TrueBlot reagents as described.5, 19 Hepa 1-6 cells were transduced with the shRNA-expressing lentivirus (Sigma-Aldrich, St. Louis, MO), and stable cell lines were generated by selection with puromycin for 2 weeks. For in vivo silencing experiments, 3-month-old mice were injected via the tail vein with C/EBPβ siRNA or nontarget siRNA (50 Ixazomib price μg of siRNA from Dharmcon complexed with in vivo-jet PEI, N/P ratio of 6 per mouse). FXR/SHP KO mice have hepatobiliary dysfunctions, including increased liver proliferation16 and development of liver cancer at age of 12 months (Anakk et al., submitted for publication). Because gankyrin-mediated elimination of C/EBPα is one of the key events in the development of liver cancer,5 we examined whether this pathway is activated in the livers of FXR/SHP KO mice. Figure 1A shows a typical liver of a 17-month-old FXR/SHP KO mouse with advanced cancer. BrdU uptake confirmed that liver proliferation was increased in these animals (Fig. 1B). Because C/EBPα needs to be phosphorylated at S193 by cdc2 and cdk4 to be degraded by gankyrin,5 we examined the expression of C/EBPα, gankyrin, cdc2, and cdk4 in livers of FXR/SHP KO mice. Figure 1C shows that gankyrin was elevated in the livers of FXR/SHP KO mice.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>